Allianz SE bought a new position in shares of Qiagen N.V. (NYSE:QGEN – Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 49,618 shares of the company’s stock, valued at approximately $2,176,000.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Allworth Financial LP increased its stake in shares of Qiagen by 14.8% in the 3rd quarter. Allworth Financial LP now owns 2,114 shares of the company’s stock worth $93,000 after acquiring an additional 273 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Qiagen by 1.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 15,722 shares of the company’s stock worth $691,000 after acquiring an additional 286 shares during the period. EverSource Wealth Advisors LLC raised its holdings in shares of Qiagen by 46.8% during the 1st quarter. EverSource Wealth Advisors LLC now owns 2,746 shares of the company’s stock worth $110,000 after acquiring an additional 876 shares during the period. First Command Advisory Services Inc. boosted its position in shares of Qiagen by 2,190.0% during the 3rd quarter. First Command Advisory Services Inc. now owns 916 shares of the company’s stock valued at $40,000 after acquiring an additional 876 shares during the last quarter. Finally, Maryland State Retirement & Pension System raised its stake in Qiagen by 7.6% during the third quarter. Maryland State Retirement & Pension System now owns 13,384 shares of the company’s stock worth $586,000 after purchasing an additional 944 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities analysts have weighed in on QGEN shares. Morgan Stanley reiterated an “overweight” rating on shares of Qiagen in a report on Friday, September 11th. Citigroup restated a “neutral” rating and set a $52.00 price target (up from $45.00) on shares of Qiagen in a report on Monday, October 26th. DZ Bank downgraded shares of Qiagen from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 22nd. Jefferies Financial Group reaffirmed a “buy” rating and set a $48.00 price target on shares of Qiagen in a research report on Thursday, August 6th. Finally, UBS Group upped their price objective on Qiagen from $48.00 to $50.00 and gave the company a “neutral” rating in a report on Friday, November 13th. Four analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $46.34.
Qiagen Stock Performance
Shares of QGEN opened at $49.30 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.14 and a current ratio of 2.63. Qiagen N.V. has a 1 year low of $32.53 and a 1 year high of $57.81. The stock has a market capitalization of $10.16 billion, a PE ratio of 26.94, a PEG ratio of 3.95 and a beta of 0.56. The stock has a 50-day simple moving average of $47.21 and a 200-day simple moving average of $42.57.
Qiagen (NYSE:QGEN – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $0.65 EPS for the quarter, beating analysts’ consensus estimates of $0.63 by $0.02. The company had revenue of $547.87 million for the quarter, compared to the consensus estimate of $538.61 million. Qiagen had a net margin of 18.19% and a return on equity of 14.70%. The company’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.61 EPS. On average, analysts predict that Qiagen N.V. will post 2.44 earnings per share for the current fiscal year.
About Qiagen
QIAGEN is a life sciences company that develops technologies used to prepare and analyze biological samples. Its products help researchers and clinicians extract and process DNA, RNA and proteins from samples such as blood, tissue and other biological materials. The company offers laboratory consumables, instruments and software for molecular diagnostics and life sciences research, as well as applications in pharmaceutical research and applied testing. Its portfolio includes sample-preparation kits, molecular testing assays and platforms for PCR, digital PCR and next-generation sequencing.
Further Reading
- Five stocks we like better than Qiagen
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.
